Probiotic (VSL#3) for Gulf War Illness

Abstract

The overall objective of the study was to determine whether Bifidobacterium infantis 35624 (Align ) will improve symptoms of GW illness. We have not started the study as yet. This is due to inability to get IND (Investigational New Drug) number for the probiotic, Bifidobacterium infantis 35624 (Align ). The manufactures of Bifidobacterium infantis 35624 (Align ), Procter & Gamble could not provide the necessary manufacturing information to Food and Drug Administration (FDA). We requested the Department of Defense to allow us to use another commonly used probiotic, VSL#3. The Department of Defense contract has been modified to include this change. The Confidentiality Disclosure Agreement between VSL Pharmaceuticals and the Department of Veterans Affairs has been agreed.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2011
Accession Number
ADA555241

Entities

People

  • Ashok K Tuteja

Organizations

  • Western Institute For Biomedical Research

Tags

DTIC Thesaurus Topics

  • Actinobacteria
  • Agreements
  • Anxiety Disorders
  • Biomedical Research
  • Colonic Diseases
  • Contracts
  • Department Of Defense
  • Department Of Veterans Affairs
  • Diseases And Disorders
  • Gastroenteritis
  • Gut Microbiome
  • Institutional Review Board
  • Manufacturing
  • Microorganisms
  • Persian Gulf Syndrome
  • Traumatic Stress Disorder

Readers

  • Clinical Trial Research.
  • Defense Acquisition Program Management
  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.